I regard this news from Pfizer as a positive as it signals that a major player in the business of vaccines believes that new drugs are and will continue to be needed for covid despite global immunisation programs.

If their drug (a protease inhibitor having a similar mode of action to some HIV drugs) is effective there would still be plenty of room for ABL. In fact, given that they would have different mechanisms of action (protease inhibitor reducing viral replication, and ABL reducing ACE2 receptors and suppressing cytokine storms) they might very well be given together. I don't see them as potential competitors, more likely as partners.